Biotech Values

[mcbio]

Re: VRUS - PSI-938 (vs. IDX184)

Curiously, VRUS’ phase-1b trial runs for seven days, which is four days longer than the typical 3-day limit imposed by the FDA for US monotherapy studies in HCV patients.

I was curious about the 7-day timeframe as well. Let me know what you find out on this point.

VRUS appears to be making a big deal about PSI-938 being potent against the 'S282T mutant' (#msg-52714527). Do you know how common this mutant is and if IDX184 is also potent against this mutant? If not, do you see this being a differentiating factor for VRUS that could cause big pharma to overlook IDX184 for PSI-938 notwithstanding the fact that PSI-938 is much further behind in the clinic?